REHOVOT, Israel, November 30, 2021 / PRNewswire / – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced that preclinical data on naptumomab estafenatox (NAP) enhancing the potency of CAR-T cells was presented on 12 november at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) at the Walter E. Washington Convention Center, Washington CC

CAR-T clinical therapy currently has limited efficacy against solid tumors due to low traffic to the tumor, limited cell expansion in patients, tumor antigen heterogeneity, and a microenvironment. immunosuppressant. NeoTX presented data which shows that NAP generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro. NAP is a fusion protein that consists of genetically engineered superantigens (Sag) linked to antigen-binding (Fab) fragments directed to tumor-associated antigens, transforms “cold tumors” into heat and, in models preclinical, can lead to long-term memory. answers.

The ability of NAP administration to activate T cells outside of the immunosuppressive microenvironment, promote infiltration of T cells into the tumor, and induce long-term memory responses strongly suggests that the combination of CAR-T cells with NAP can overcome the limited effect of CAR-T therapy against solid tumors. To access the poster presented, please click here.

About NeoTX

NeoTX is a clinical-stage immuno-oncology company developing targeted cancer immunotherapies using its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically modified bacterial determinant to the tumor surface while simultaneously activating and growing tumor-specific immune cells which are then redirected from the periphery to the tumor to trigger an immune response. The company’s primary TTS molecule, naptumomab estafenaox (NAP), is currently in clinical development for non-small cell lung cancer and other solid tumors. For more information, please visit www.neotx.com

Media contact:

Aviram uzi
Head of public relations and communications
Gelbart-Kahana Investor Relations
[email protected]
+ 972-525329103

Investor contact:

Robert harow, head of operations
NeoTX Therapeutics Ltd
[email protected]
609-718-2305 ext 204

Cision

View original content: https://www.prnewswire.com/news-releases/data-on-naptumomab-estafenatox-nap-enhancing-car-t-cells-potency-presented-by-neotx-at-sitc-2021 – annual-meeting-301433680.html

SOURCE NeoTX


Source link